Real-world evidence for pembrolizumab in non-small cell lung cancer: a nationwide cohort study
Our nationwide study demonstrated a survival benefit over conventional chemotherapy of a similar magnitude as observed in clinical trials and confirms the effectiveness of pembrolizumab in routine clinical practice.
Authors
- Yngvar Nilssen (ORCID: https://orcid.org/0000-0002-3620-1555)
- Odd Terje Brustugun (ORCID: https://orcid.org/0000-0002-5153-8391)
- Lars Fjellbirkeland
- Bettina Kulle Andreassen
- Helga Helseth Hektoen (ORCID: https://orcid.org/0000-0002-2002-0944)
- Kaitlyn M. Tsuruda (ORCID: https://orcid.org/0000-0001-8749-6237)
Institutions
- Oslo University Hospital (NO)
- Norwegian Institute of Public Health (NO)
- University of Oslo (NO)
- Drammen Hospital (NO)
- Cancer Registry of Norway (NO)
Publication Details
- Journal
- British Journal of Cancer
- Published
- 2024-11-03
- DOI
- https://doi.org/10.1038/s41416-024-02895-1
- Citations
- 16
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 4.52
Funders
- Helse Sør-Øst RHF